Download PDF
Thromb Haemost 2008; 99(04): 779-781
DOI: 10.1160/TH07-09-0573
Case Report
Schattauer GmbH

Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT)

Eugenia Rota
1   Neurology Unit, S. Croce Hospital, Mondovì (CN), Italy
,
Mario Bazzan
2   Haematology and Thrombosis Unit, Cellini Humanitas Hospital, Turin, Italy
,
Giovanni Fantino
3   Surgery Dept., S. Spirito Hospital, Bra (CN), Italy
› Author Affiliations
Further Information

Publication History

Received: 20 September 2007

Accepted after major revision: 28 February 2008

Publication Date:
25 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Arepally GM, Ortel TL. Heparin-induced thrombocytopenia. N Eng J Med 2006; 355: 809-817.
    CrossrefPubMedGoogle Scholar
  • 2 Harenberg J, Jörg I, Fenyvesi T. Heparin-induced thrombocytopenia: pathophysiology and new treatment options. Pathophysiol Haemost Thromb 2002; 32: 289-294.
    CrossrefPubMedGoogle Scholar
  • 3 Warkentin TE. Heparin-induced thrombocytopenia: Yet another treatment paradox?. Thromb Haemost 2001; 85: 947-949.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a metaanalysis. Blood 2005; 106: 2710-2715.
    CrossrefPubMedGoogle Scholar
  • 5 Warkentin TE, Sheppard JA, Sigouin CS. et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood 2006; 108: 2937-2941.
    CrossrefPubMedGoogle Scholar
  • 6 Prandoni P, Siragusa S, Girolami B. et al. For the BELZONI Investigators Group. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular weight heparin. A prospective cohort study. Blood 2005; 106: 3049-3054.
    CrossrefPubMedGoogle Scholar
  • 7 Turpie AG, Gallus AS, Hoek JA. A synthetic pentasaccharide for the prevention of deep vein thrombosis after total hip replacement. N Eng J Med 2001; 344: 619-625.
    CrossrefPubMedGoogle Scholar
  • 8 Becattini C, Agnelli G, Emmerich J. et al. Initial treatment of venous thromboembolism. Thromb Haemost 2006; 96: 242-250.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Warkentin TE, Cook RJ, Marder VJ. et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005; 106: 3791-3796.
    CrossrefPubMedGoogle Scholar
  • 10 D’Angelo A, Della Valle P, Fattorini A. et al. Disappearance of anti-PF4/heparin antibodies under prolonged fondaparinux administration was observed in a patient with DVT developed in the context of a LWMHinduced thrombocytopenia. Thromb Haemost 2006; 95: 573-575.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Efird LE, Kockler DR. Fondaparinux for thromboembolic treatment and prophylaxis of heparin-induced thrombocytopenia. Ann Pharmacother 2006; 40: 1383-1387.
    CrossrefPubMedGoogle Scholar
  • 12 Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with Fondaparinux. N Eng J Med 2007; 356: 2653-2654.
    CrossrefPubMedGoogle Scholar
  • 13 Gruel Y, Lang M, Darnige L. et al. Fatal effect of reexposure to heparin after previous heparin-associated thrombocytopenia and thrombosis. Lancet 1990; 336: 1077-1078.
    PubMedGoogle Scholar